NEW YORK – Single-cell assay developer BioSkryb said on Tuesday that it has signed an agreement to distribute its ResolveDNA genome amplification technology together with ALS Automated Lab Solutions' ALS CellCelector cell imaging and picking platform in the US.
ResolveDNA uses a proprietary technology called primary template-directed amplification that is designed to recover over 95 percent of single-cell genomes and low-input samples with high accuracy and uniformity. The CellCelector platform combines automated inverted fluorescence microscopy with high-speed scanning, high-precision microfluidic cell picking robotics, and image processing software.
According to BioSkryb, the combined offering will enable single-cell genomic research using cells isolated at specific locations. The company is also working with Jena, Germany-based ALS to extend the use of the two technologies to intact tissue specimens.
Durham, North Carolina-based BioSkryb said it will launch an early-access program for researchers to acquire the combined workflow. Financial and other terms of the deal were not disclosed.
"This will be a breakthrough for researchers and clinicians, and eventually for patients, because in one experiment we will be able to achieve high resolution single-cell omics of critical cells, while retaining the context of where those cells interact with other cells and critical landmarks within the tissue sample," BioSkryb Cofounder and CEO Jay West said in a statement. "With this expanded distribution agreement between BioSkryb and ALS, we will be offering an understanding of the micro with the macro that can help accelerate genomic insights in the fields of pathology, diagnostics, and drug discovery, that can ultimately improve patient care."